Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Digoxin vs Digoxin+ BEM/RZR vs Digoxin+ 2h BEM/RZR · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Digoxin vs Digoxin + BEM/RZR vs Digoxin + 2h BEM/RZR | EXPERIMENTAL | - |
| Rosuvastatin vs Rosuvastatin + BEM/RZR vs Rosuvastatin + 2h BEM/RZR | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Digoxin vs Digoxin + BEM/RZR vs Digoxin + 2h BEM/RZR | DRUG | Treatment-A (Digoxin): A single dose of digoxin will be administered under fasting conditions. Treatment-B (Digoxin + BEM/RZR): A single dose of digoxin will be co-administered a single dose of BEM/RZR under fasting conditions. Treatment-C (Digoxin + 2h BEM/RZR): A single dose of digoxin will be administered under fasting conditions. Then, a single dose of BEM/RZR will be administered approximately 2 hours later under fasting conditions. |
| Rosuvastatin vs Rosuvastatin + BEM/RZR vs Rosuvastatin + 2h BEM/RZR | DRUG | Treatment-D (rosuvastatin): A single dose of rosuvastatin will be administered under fasting conditions. Treatment-E (rosuvastatin + BEM/RZR): A single dose of rosuvastatin will be co-administered with a single dose BEM/RZR under fasting conditions. Treatment-F (rosuvastatin + 2h BEM/RZR): A single dose of rosuvastatin will be administered under fasting conditions. Then, a single dose BEM/RZR will be administered approximately 2 hours later under fasting conditions. |
Inclusion Criteria: * Must agree to use two methods of birth control from Screening through 90 days after administration of the last dose of study drug. * Minimum body weight of 50 kg and body mass index (BMI) of 18-30 kg/m2. * Willing to comply with the study requirements and to provide written in...